Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 24;32(4):211–220. doi: 10.1177/0891988719841728

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 4. — Concentrations of IL-1β, sIL-1RI, sIL-1RII, and IL-1Ra in plasma of patients with AD. Levels of IL-1β, sIL-1RI, sIL-1RII, and IL-1Ra were quantified by ELISA in plasma. Results are depicted as median [interquartile ranges]. Significance was calculated with the nonparametric Mann-Whitney U test. Values below the lower limit of quantification were set to the lower limit of quantification (IL-1RI: 60 pg/mL, IL-1RII: 250 pg/mL, IL-1Ra: 115 pg/mL). *P < .05. AD indicates Alzheimer disease; IL-1Ra, interleukin 1 receptor antagonist; IL-1RI, interleukin 1 receptor subtype I; IL-1RII indicates interleukin 1 receptor subtype II; IL-1RII, interleukin 1 receptor subtype II; IL-1Ra, interleukin 1 receptor antagonist; SC, symptomatic controls; sIL-1RI, soluble interleukin 1 receptor subtype I; sIL-1RII, soluble interleukin 1 receptor subtype II.